Jiangsu Hengrui Medicine Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Jiangsu Hengrui Medicine Co., Ltd. carries a market capitalization of 353.72B, placing it among publicly traded companies globally. Its enterprise value stands at 288.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 353.72B |
| Enterprise Value | 288.64B |
Share Statistics
Jiangsu Hengrui Medicine Co., Ltd. currently has 6.64B shares outstanding.
| Shares Outstanding | 6.64B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Jiangsu Hengrui Medicine Co., Ltd. trades at a trailing price-to-earnings ratio of 44.08. The price-to-sales ratio is 10.76, and the price-to-book ratio stands at 7.42.
| PE Ratio | 44.08 |
| PS Ratio | 10.76 |
| PB Ratio | 7.42 |
| P/TBV Ratio | 6.09 |
| P/FCF Ratio | 142.69 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Jiangsu Hengrui Medicine Co., Ltd. trades at an EV/EBITDA multiple of 36.09 and an EV/FCF ratio of 126.36. The EV/Sales ratio of 9.57 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 36.09 provides insight into valuation relative to core operating earnings.
| EV / Sales | 9.57 |
| EV / EBITDA | 36.09 |
| EV / EBIT | 36.09 |
| EV / FCF | 126.36 |
Financial Position
Jiangsu Hengrui Medicine Co., Ltd. maintains a current ratio of 13.49, meaning it holds 13.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.15, indicating conservative leverage, while an interest coverage ratio of 575.08 demonstrates strong ability to service its debt obligations.
| Current Ratio | 13.49 |
| Quick Ratio | 10.46 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 0.01 |
| Interest Coverage | 575.08 |
Financial Efficiency
Jiangsu Hengrui Medicine Co., Ltd. posts a return on equity of 18.16 and a return on invested capital of 13.51.
| Return on Equity (ROE) | 18.16 |
| Return on Assets (ROA) | 13.24 |
| Return on Invested Capital (ROIC) | 13.51 |
| Return on Capital Employed (ROCE) | 17.87 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.69 |
Taxes
Over the trailing twelve months, Jiangsu Hengrui Medicine Co., Ltd. has paid 1.11B in income taxes, reflecting an effective tax rate of 13.05.
| Income Tax | 1.11B |
| Effective Tax Rate | 13.05 |
Stock Price Statistics
Jiangsu Hengrui Medicine Co., Ltd.'s stock has gained approximately 5.31814% over the past 52 weeks. The 50-day moving average sits at 51.07, while the 200-day moving average is 58.13.
| Beta (5Y) | N/A |
| 52-Week Price Change | 5.31814% |
| 50-Day Moving Average | 51.07 |
| 200-Day Moving Average | 58.13 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Jiangsu Hengrui Medicine Co., Ltd. generated 30.15B in revenue and converted that into 7.35B in net income, yielding earnings per share of 1.18. EBITDA reached 8.00B, while operating income came in at 8.00B.
| Revenue | 30.15B |
| Gross Profit | 26.06B |
| Operating Income | 8.00B |
| Pretax Income | 8.47B |
| Net Income | 7.35B |
| EBITDA | 8.00B |
| EBIT | 8.00B |
| Earnings Per Share (EPS) | 1.18 |
Balance Sheet
Jiangsu Hengrui Medicine Co., Ltd. holds 36.23B in cash and equivalents against 91.43M in total debt, resulting in a net debt position of -36.12B. Total book value stands at 43.68B, with working capital of 43.30B providing operational flexibility.
| Cash & Cash Equivalents | 36.23B |
| Total Debt | 91.43M |
| Net Debt | -36.12B |
| Equity (Book Value) | 43.68B |
| Book Value Per Share | 6.99 |
| Working Capital | 43.30B |
Cash Flow
After subtracting -2.27B in capital expenditures, free cash flow totaled -2.27B - equivalent to -0.36 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -2.27B |
| Free Cash Flow | -2.27B |
| FCF Per Share | -0.36 |
Margins
Jiangsu Hengrui Medicine Co., Ltd. operates with a gross margin of 86.43, reflecting its pricing power and cost economics. The operating margin of 26.53 and net profit margin of 24.40 provide insight into operational efficiency.
| Gross Margin | 86.43 |
| Operating Margin | 26.53 |
| Pretax Margin | 28.09 |
| Profit Margin | 24.40 |
| EBITDA Margin | 26.53 |
Dividends & Yields
The company's payout ratio of 17.28 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.20 |
| Dividend Yield | N/A |
| Payout Ratio | 17.28 |
| Shareholder Yield | -2.04 |
| FCF Yield | 0.70 |
Stock Splits
Jiangsu Hengrui Medicine Co., Ltd.'s most recent stock split took place on June 10, 2021 with a 5:6 split ratio.
| Last Split Date | 6/10/2021 |
| Split Ratio | 5:6 |
Scores
Jiangsu Hengrui Medicine Co., Ltd. posts an Altman Z-Score of 53.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 53.15 |